Pacira BioSciences (NASDAQ:PCRX) Target Lowered by BMO Capital Markets to $60.00

Pacira BioSciences stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by BMO Capital Markets on 10/12/2021. In a note to investors, the firm issued a new target price of $60.00. The analysts previously had $66.00 target price. BMO Capital Markets’s price target would indicate a potential upside of 18.20% from the stock’s previous close.

Shares of traded on monday, reaching $51.00. 72186 shares of the stock traded hands, compared to its average volume of 512818. On monday, Shares of closed at $51.00. The firm’s 50 day moving average is $56.40 and its 200 day moving average is $63.36.  has a 12 month low of $45.05 and a 12 month high of $80.00. While on yearly highs and lows, today has traded high as $51.51 and has touched $49.62 on the downward trend.

Earnings and What to expect: 

Pacira BioSciences last released its earnings results on August 2nd, 2021. The reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.03. The firm had revenue of $135.60 million for the quarter, compared to analyst estimates of $135.02 million. Its quarterly revenue was up 79.6% on a year-over-year basis. Pacira BioSciences has generated $1.30 earnings per share over the last year ($3.91 diluted earnings per share) and currently has a price-to-earnings ratio of 13.0. Earnings for Pacira BioSciences are expected to grow by 40.50% in the coming year, from $2.00 to $2.81 per share. Pacira BioSciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Pacira BioSciences are expected to grow by 40.50% in the coming year, from $2.00 to $2.81 per share. The P/E ratio of Pacira BioSciences is 12.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 14.27. The P/E ratio of Pacira BioSciences is 12.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.64. Pacira BioSciences has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

(NASDAQ:PCRX) Moving Average Technical Analysis

5 day Moving Average is $$49.41 And 5 day price change is $2.55 (5.29%)  with average volume for 5 day average is 572,224. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $54.13 and 20 day price change is -$3.88 (-7.10%) and average 20 day moving volume is 577,721. 50 day moving average is $56.40  and 50 day price change is -$8.46 ( -14.29%)  and with average volume for 50 days is : 453,090. 200 day moving average is $63.36  and 200 day price change is -$8.46 (-14.29%)  and with average volume for 200 days is : 450,661.

Other owners latest trading in Pacira BioSciences :

  • On 10/7/2021 shares held by State of Alaska Department of Revenue were 32,427 which equates to market value of $1.82M and appx 0.00% owners of Pacira BioSciences
  • On 10/6/2021 shares held by IFP Advisors Inc were 695 which equates to market value of $39K and appx 0.00% owners of Pacira BioSciences
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 171,189 which equates to market value of $10.39M and appx 0.00% owners of Pacira BioSciences
  • In total Institutional ownership equates to There is no enough data Institutional Ownership Percentage for Pacira BioSciences

See More Analyst Rating at: RATING